| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-05-2539 |
| P698 | PubMed publication ID | 16609061 |
| P2093 | author name string | Michael B Atkins | |
| James W Mier | |||
| David J Panka | |||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 7 Pt 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2371s-2375s | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma | |
| P478 | volume | 12 |
| Q35684276 | A Potent Inhibitor of Phosphoinositide 3-Kinase (PI3K) and Mitogen Activated Protein (MAP) Kinase Signalling, Quercetin (3, 3', 4', 5, 7-Pentahydroxyflavone) Promotes Cell Death in Ultraviolet (UV)-B-Irradiated B16F10 Melanoma Cells |
| Q33621880 | A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. |
| Q28547323 | A network flow-based method to predict anticancer drug sensitivity |
| Q34615116 | A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets |
| Q34545490 | Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS |
| Q39002838 | Cell Signaling Pathways That Regulate Antigen Presentation |
| Q39739265 | Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma |
| Q90703603 | Circ-RPL15: a plasma circular RNA as novel oncogenic driver to promote progression of chronic lymphocytic leukemia |
| Q34078634 | Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells |
| Q34622439 | Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses |
| Q27022355 | Current and future trials of targeted therapies in cutaneous melanoma |
| Q45954926 | Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species. |
| Q39868014 | Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells |
| Q47113667 | Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation |
| Q39934736 | Enhancement of apoptotic damage of squamous cell carcinoma cells by inhibition of the mitochondrial DNA repairing system |
| Q26859314 | Exogenous endophthalmitis in diabetic patients: a systemic review |
| Q41941878 | Expression and function of bcl-2 proteins in melanoma |
| Q24302321 | GRP78 and Raf-1 cooperatively confer resistance to endoplasmic reticulum stress-induced apoptosis |
| Q38722005 | Gap junction protein connexin43 deregulation contributes to bladder carcinogenesis via targeting MAPK pathway |
| Q34101036 | Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals |
| Q99552126 | Identification, Validation, and Functional Annotations of Genome-Wide Profile Variation between Melanocytic Nevus and Malignant Melanoma |
| Q35027565 | Impaired epithelial wound healing and EGFR signaling pathways in the corneas of diabetic rats |
| Q39039916 | Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. |
| Q54654151 | Involvement of c‐Jun N‐terminal kinase and extracellular signal‐regulated kinase 1/2 in EGF‐induced angiogenesis |
| Q37310645 | Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours |
| Q37609790 | Metformin targets multiple signaling pathways in cancer |
| Q38886902 | PM2.5-induced oxidative stress increases adhesion molecules expression in human endothelial cells through the ERK/AKT/NF-κB-dependent pathway |
| Q37417526 | Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis |
| Q53430932 | Proteinase-activated receptor-1 mediates allogeneic CD8(+) T cell-induced apoptosis of vascular endothelial cells. |
| Q39976653 | RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells |
| Q37024839 | Recent discoveries in the genetics of melanoma and their therapeutic implications |
| Q28601717 | Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation |
| Q24596060 | Regulation of protein phosphorylation within the MKK1-ERK2 complex by MP1 and the MP1*P14 heterodimer |
| Q36735369 | Role of raf-1 kinase in diabetes-induced accelerated apoptosis of retinal capillary cells |
| Q54705317 | Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. |
| Q38396518 | Sprouty2 is associated with prognosis and suppresses cell proliferation and invasion in renal cell carcinoma |
| Q35828643 | Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation |
| Q92663940 | Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q55692966 | Targeting TRPV1 to relieve motion sickness symptoms in mice by electroacupuncture and gene deletion. |
| Q37745182 | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail |
| Q51746852 | Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. |
| Q24656947 | The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis |
| Q40094333 | Thimerosal-induced apoptosis in human SCM1 gastric cancer cells: activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca2+]i elevation |
| Q38304271 | Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma |
| Q37406217 | Use of liposomes as drug delivery vehicles for treatment of melanoma. |
| Q37766212 | miRNAs as therapeutic targets in ischemic heart disease |
Search more.